Skip to main content
Erschienen in: European Journal of Epidemiology 2/2014

01.02.2014 | CANCER

Prospective associations between serum biomarkers of lipid metabolism and overall, breast and prostate cancer risk

verfasst von: Mathilde His, Laurent Zelek, Mélanie Deschasaux, Camille Pouchieu, Emmanuelle Kesse-Guyot, Serge Hercberg, Pilar Galan, Paule Latino-Martel, Jacques Blacher, Mathilde Touvier

Erschienen in: European Journal of Epidemiology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Experimental studies provided evidence about mechanisms by which cholesterol, especially high density lipoprotein cholesterol (HDL-C), could influence carcinogenesis, notably through antioxidant and anti-inflammatory properties. However, prospective studies that investigated the associations between specific lipid metabolism biomarkers and cancer risk provided inconsistent results. The objective was to investigate the prospective associations between total cholesterol (T-C), HDL-C, low density lipoprotein cholesterol, apolipoproteins A1 (apoA1) and B, and triglycerides and overall, breast and prostate cancer risk. Analyses were performed on 7,557 subjects of the Supplémentation en Vitamines et Minéraux Antioxydants Study, a nationwide French cohort study. Biomarkers of lipid metabolism were measured at baseline and analyzed regarding the risk of first primary incident cancer (N = 514 cases diagnosed during follow-up, 1994–2007), using Cox proportional hazards models. T-C was inversely associated with overall (HR1mmol/L increment = 0.91, 95 % CI 0.82–1.00; P = 0.04) and breast (HR1mmol/L increment = 0.83, 95 % CI 0.69–0.99; P = 0.04) cancer risk. HDL-C was also inversely associated with overall (HR1mmol/L increment = 0.61, 95 % CI 0.46–0.82; P = 0.0008) and breast (HR1mmol/L increment = 0.48, 95 % CI 0.28–0.83; P = 0.009) cancer risk. Consistently, apoA1 was inversely associated with overall (HR1g/L increment = 0.56, 95 % CI 0.39–0.82; P = 0.003) and breast (HR1g/L increment = 0.36, 95 % CI 0.18–0.73; P = 0.004) cancer risk. This prospective study suggests that pre-diagnostic serum levels of T-C, HDL-C and ApoA1 are associated with decreased overall and breast cancer risk. The confirmation of a role of cholesterol components in cancer development, by further large prospective and experimental studies, may have important implications in terms of public health, since cholesterol is already crucial in cardiovascular prevention.

Literatur
  1. Huxley R, Lewington S, Clarke R. Cholesterol, coronary heart disease and stroke: a review of published evidence from observational studies and randomized controlled trials. Semin Vasc Med. 2002;2:315–23.PubMedView Article
  2. Law MR, Thompson SG. Low serum cholesterol and the risk of cancer: an analysis of the published prospective studies. Cancer Causes Control. 1991;2:253–61.PubMedView Article
  3. Melvin JC, Holmberg L, Rohrmann S, et al. Serum lipid profiles and cancer risk in the context of obesity: four meta-analyses. J Cancer Epidemiol. 2013;2013:823849.PubMed CentralPubMedView Article
  4. Bjorge T, Lukanova A, Tretli S, et al. Metabolic risk factors and ovarian cancer in the metabolic syndrome and cancer project. Int J Epidemiol. 2011;40:1667–77.PubMedView Article
  5. Eichholzer M, Stahelin HB, Gutzwiller F, et al. Association of low plasma cholesterol with mortality for cancer at various sites in men: 17-y follow-up of the prospective Basel study. Am J Clin Nutr. 2000;71:569–74.PubMed
  6. Nago N, Ishikawa S, Goto T, et al. Low cholesterol is associated with mortality from stroke, heart disease, and cancer: the Jichi Medical School Cohort Study. J Epidemiol. 2011;21:67–74.PubMed CentralPubMedView Article
  7. Strohmaier S, Edlinger M, Manjer J, et al. Total serum cholesterol and cancer incidence in the metabolic syndrome and cancer project (Me-Can). PLoS One. 2013;8:e54242.PubMed CentralPubMedView Article
  8. Kitahara CM, de Berrington GA, Freedman ND, et al. Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol. 2011;29:1592–8.PubMed CentralPubMedView Article
  9. Iso H, Ikeda A, Inoue M, et al. Serum cholesterol levels in relation to the incidence of cancer: the JPHC study cohorts. Int J Cancer. 2009;125:2679–86.PubMedView Article
  10. Jacobs EJ, Gapstur SM. Cholesterol and cancer: answers and new questions. Cancer Epidemiol Biomarkers Prev. 2009;18:2805–6.PubMedView Article
  11. Henriksson P, Eriksson M, Ericsson S, et al. Hypocholesterolaemia and increased elimination of low-density lipoproteins in metastatic cancer of the prostate. Lancet. 1989;2:1178–80.PubMedView Article
  12. Vitols S, Gahrton G, Bjorkholm M, et al. Hypocholesterolaemia in malignancy due to elevated low-density-lipoprotein-receptor activity in tumour cells: evidence from studies in patients with leukaemia. Lancet. 1985;2:1150–4.PubMedView Article
  13. Dessi S, Batetta B, Pulisci D, et al. Altered pattern of lipid metabolism in patients with lung cancer. Oncology. 1992;49:436–41.PubMedView Article
  14. Ahn J, Lim U, Weinstein SJ, et al. Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer. Cancer Epidemiol Biomarkers Prev. 2009;18:2814–21.PubMed CentralPubMedView Article
  15. Soran H, Hama S, Yadav R, et al. HDL functionality. Curr Opin Lipidol. 2012;23:353–66.PubMedView Article
  16. von Eckardstein A, Hersberger M, Rohrer L. Current understanding of the metabolism and biological actions of HDL. Curr Opin Clin Nutr Metab Care. 2005;8:147–52.View Article
  17. Agnoli C, Berrino F, Abagnato CA, et al. Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: a nested case–control study. Nutr Metab Cardiovasc Dis. 2010;20:41–8.PubMed CentralPubMedView Article
  18. Furberg AS, Veierod MB, Wilsgaard T, et al. Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk. J Natl Cancer Inst. 2004;96:1152–60.PubMedView Article
  19. Gaard M, Tretli S, Urdal P. Risk of breast cancer in relation to blood lipids: a prospective study of 31,209 Norwegian women. Cancer Causes Control. 1994;5:501–9.PubMedView Article
  20. Hoyer AP, Engholm G. Serum lipids and breast cancer risk: a cohort study of 5,207 Danish women. Cancer Causes Control. 1992;3:403–8.PubMedView Article
  21. Inoue M, Noda M, Kurahashi N, et al. Impact of metabolic factors on subsequent cancer risk: results from a large-scale population-based cohort study in Japan. Eur J Cancer Prev. 2009;18:240–7.PubMedView Article
  22. Kucharska-Newton AM, Rosamond WD, Mink PJ, et al. HDL-cholesterol and incidence of breast cancer in the ARIC cohort study. Ann Epidemiol. 2008;18:671–7.PubMed CentralPubMedView Article
  23. Melvin JC, Seth D, Holmberg L, et al. Lipid profiles and risk of breast and ovarian cancer in the Swedish AMORIS study. Cancer Epidemiol Biomarkers Prev. 2012;21:1381–4.PubMedView Article
  24. Moorman PG, Hulka BS, Hiatt RA, et al. Association between high-density lipoprotein cholesterol and breast cancer varies by menopausal status. Cancer Epidemiol Biomarkers Prev. 1998;7:483–8.PubMed
  25. Esposito K, Chiodini P, Capuano A, et al. Metabolic syndrome and postmenopausal breast cancer: systematic review and meta-analysis. Menopause. 2013;20:1301–9.PubMedView Article
  26. Mondul AM, Weinstein SJ, Virtamo J, et al. Serum total and HDL cholesterol and risk of prostate cancer. Cancer Causes Control. 2011;22:1545–52.PubMed CentralPubMedView Article
  27. Van Hemelrijck M, Walldius G, Jungner I, et al. Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study. Cancer Causes Control. 2011;22:1011–9.PubMedView Article
  28. Esposito K, Chiodini P, Capuano A, et al. Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis. J Endocrinol Invest. 2013;36:132–9.PubMed
  29. Hercberg S, Galan P, Preziosi P, et al. The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Intern Med. 2004;164:2335–42.PubMedView Article
  30. Stamey TA. Second Stanford conference on international standardization of prostate-specific antigen immunoassays: September 1 and 2, 1994. Urology. 1995;45:173–84.PubMedView Article
  31. Le Moullec N, Deheeger M, Preziosi P, et al. Validation du manuel photos utilisé pour l’enquête alimentaire de l’étude SU.VI.MAX. Cah Nutr Diet. 1996;31:158–64.
  32. Hercberg S. Table de composition SU.VI.MAX des aliments. Paris: Les éditions INSERM/Economica; 2005.
  33. Kritchevsky SB, Wilcosky TC, Morris DL, et al. Changes in plasma lipid and lipoprotein cholesterol and weight prior to the diagnosis of cancer. Cancer Res. 1991;51:3198–203.PubMed
  34. Planella T, Cortes M, Martinez-Bru C, et al. Calculation of LDL-cholesterol by using apolipoprotein B for classification of nonchylomicronemic dyslipemia. Clin Chem. 1997;43:808–15.PubMed
  35. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.PubMed
  36. Huang R, Silva RA, Jerome WG, et al. Apolipoprotein A–I structural organization in high-density lipoproteins isolated from human plasma. Nat Struct Mol Biol. 2011;18:416–22.PubMed CentralPubMedView Article
  37. Aleksandrova K, Boeing H, Jenab M, et al. Metabolic syndrome and risks of colon and rectal cancer: the European prospective investigation into cancer and nutrition study. Cancer Prev Res (Phila). 2011;4:1873–83.View Article
  38. Esposito K, Chiodini P, Capuano A, et al. Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine. 2013;. doi:10.​1007/​s12020-013-9973-3.
  39. Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–90.PubMedView Article
  40. Schatzkin A, Hoover RN, Taylor PR, et al. Serum cholesterol and cancer in the NHANES I epidemiologic followup study. National Health and Nutrition Examination Survey. Lancet. 1987;2:298–301.PubMedView Article
  41. Cleeman JI, Grundy SM, Becker D, Clark LT. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP III). Jama. 2001;285:2486–97.
  42. Leon AS, Sanchez OA. Response of blood lipids to exercise training alone or combined with dietary intervention. Med Sci Sports Exerc. 2001;33:S502–15.PubMedView Article
  43. World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, DC: AICR; 2007.
  44. Kraus WE, Houmard JA, Duscha BD, et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med. 2002;347:1483–92.PubMedView Article
  45. Esteve E, Ricart W, Fernandez-Real JM. Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clin Nutr. 2005;24:16–31.PubMedView Article
  46. Beynen AC, Katan MB, Van Zutphen LF. Hypo- and hyperresponders: individual differences in the response of serum cholesterol concentration to changes in diet. Adv Lipid Res. 1987;22:115–71.PubMed
  47. Ordovas JM, Lopez-Miranda J, Mata P, et al. Gene-diet interaction in determining plasma lipid response to dietary intervention. Atherosclerosis. 1995;118(Suppl.):S11–27.PubMedView Article
  48. Al-Delaimy WK, Jansen EH, Peeters PH, et al. Reliability of biomarkers of iron status, blood lipids, oxidative stress, vitamin D, C-reactive protein and fructosamine in two Dutch cohorts. Biomarkers. 2006;11:370–82.PubMedView Article
  49. Bairaktari E, Hatzidimou K, Tzallas C, et al. Estimation of LDL cholesterol based on the Friedewald formula and on apo B levels. Clin Biochem. 2000;33:549–55.PubMedView Article
  50. Binder-Foucard F, Belot A, Delafosse P, et al. National estimate of the incidence and mortality from cancer in France between 1980 and 2012. Part 1—solid tumors. Saint-Maurice: Institut de veille sanitaire; 2013.
  51. Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. Am Heart J. 1991;121:293–8.PubMedView Article
  52. World Health Organization. Cardiovascular diseases (CVDs). Fact sheet no. 317. In: Media centre. World Health Organization; 2013. http://​www.​who.​int/​mediacentre/​factsheets/​fs317/​en/​. Accessed 12 July 2013.
  53. World Health Organization. Cancer. Fact sheet no. 297. In: Media centre. World Health Organization. 2013. http://​www.​who.​int/​mediacentre/​factsheets/​fs297/​en/​index.​html. Accessed July 12 2013.
Metadaten
Titel
Prospective associations between serum biomarkers of lipid metabolism and overall, breast and prostate cancer risk
verfasst von
Mathilde His
Laurent Zelek
Mélanie Deschasaux
Camille Pouchieu
Emmanuelle Kesse-Guyot
Serge Hercberg
Pilar Galan
Paule Latino-Martel
Jacques Blacher
Mathilde Touvier
Publikationsdatum
01.02.2014
Verlag
Springer Netherlands
Erschienen in
European Journal of Epidemiology / Ausgabe 2/2014
Print ISSN: 0393-2990
Elektronische ISSN: 1573-7284
DOI
https://doi.org/10.1007/s10654-014-9884-5

Weitere Artikel der Ausgabe 2/2014

European Journal of Epidemiology 2/2014 Zur Ausgabe